)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Aethlon Medical (AEMD) investor relations material
Aethlon Medical Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary13 Aug, 2025
Executive summary
Advanced the Hemopurifier oncology clinical program in Australia, completing the first cohort with no device-related serious adverse events or dose-limiting toxicities; protocol amended to broaden eligibility and DSMB recommended advancing to the second cohort.
Discontinued the planned India trial to focus resources on the Australian study, conserving $500,000 to $1,000,000 and avoiding regulatory delays.
Preclinical research demonstrated over 98% removal of platelet-derived extracellular vesicles, supporting potential new indications and collaborations for Long COVID research; findings presented at major scientific conferences.
Hemopurifier holds FDA Breakthrough Device Designation for advanced cancer and life-threatening viral infections.
Operating expenses reduced by 31.6% year-over-year, enhancing operational efficiency.
Financial highlights
Cash and cash equivalents as of June 30, 2025, were approximately $3.8 million, down from $5.5 million at March 31, 2025.
Operating expenses for the quarter were $1.8 million, down 31.6% year-over-year from $2.6 million.
Net loss for the quarter was $1.76 million, compared to $2.57 million in the prior-year quarter; basic and diluted net loss per share was $0.85, compared to $2.76.
No revenue was recognized during the quarter; the company remains in a development stage.
Cost reductions driven by lower payroll, legal, and consulting expenses.
Outlook and guidance
Anticipate completion of Australian oncology trial treatments by late 2025 or early 2026, with data analysis and potential application for PMA or efficacy trial to follow.
Early data from the first patient cohort expected in September 2025.
Actively recruiting additional sites and using new initiatives to accelerate patient enrollment in Australia.
Existing cash is not expected to fund operations for twelve months from the financial statement issuance date, raising substantial doubt about going concern.
Clinical trial expenses for the Australian oncology trial and rent payments are expected to increase for the foreseeable future.
Assess timeline for Australian trial completion.
Elaborate on long COVID preclinical data.
What's the status of adding trial sites in Australia?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aethlon Medical earnings date
Q2 202612 Nov, 2025
Next Aethlon Medical earnings date
Q2 202612 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Aethlon Medical Inc develops medical devices focused on the removal of harmful substances from the blood. The company’s lead product, Hemopurifier, is designed to filter viruses, exosomes, and other pathogenic particles in therapeutic applications. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage